Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Mi | Cereno Scientific's CEO on novel therapies for rare diseases | 1 | Cision News | ||
31.10. | Cereno Scientific participates at DNB Nordic Healthcare Conference 2024 | 2 | Cision News | ||
30.10. | Cereno Scientific presents at BioStock Life Science Summit 2024 | 1 | Cision News | ||
25.10. | Edison Investment Research increases valuation of Cereno Scientific to 4.05 BSEK or SEK 14.3 SEK/share after IPF selected as initial target indication for CS014 | 2 | Cision News | ||
25.10. | Cereno Scientific - CMD highlights a 'rare' portfolio refocus | 221 | Edison Investment Research | Cereno Scientific recently held a capital markets day (CMD), providing greater insight on its development pipeline and strategic objectives. The key takeaway was its decision to focus on the rare disease... ► Artikel lesen | |
22.10. | CERENO SCIENTIFIC: BioStock has published an interview with CEO Sten R. Sörensen on IPF as the initial indication for CS014 and the Company's strengthened focus on rare diseases | 3 | Cision News | ||
22.10. | The temperature of Cereno Scientific after major news | 1 | Cision News | ||
17.10. | Cereno Scientific presents an updated agenda for the Capital Markets Day October 17th, 2024 | 1 | Cision News | ||
16.10. | Cereno Scientific to attend BIO-Europe in Stockholm, November 4-6, 2024 | 1 | Cision News | ||
15.10. | Cereno Scientific presents the agenda for the upcoming Capital Markets Day to be held October 17th, 2024 | 2 | Cision News | ||
09.10. | Cereno Scientific to present preclinical data for drug candidate CS585 at the AHA Scientific Sessions 2024 | 2 | Cision News | ||
08.10. | Invitation to Cereno Scientific's Capital Markets Day on October 17, 2024 | 3 | Cision News | ||
07.10. | Edison Investment Research publishes Executive interview with Sten R. Sörensen, CEO, Cereno Scientific, on positive topline Phase IIa results | 1 | Cision News | ||
03.10. | Cereno Scientific discusses phase IIa results for CS1 | 1 | Cision News | ||
03.10. | CERENO SCIENTIFIC: Cereno's phase IIa results positive, clear path forward | 1 | Cision News | ||
03.10. | BioStock has published an article and interview with CEO Sten R. Sörensen on the positive topline results from Cereno Scientific's Phase IIa trial on CS1 in PAH | 1 | Cision News | ||
02.10. | Cereno Scientific - CS1 shines in Phase IIa PAH trial | 224 | Edison Investment Research | Cereno Scientific has reported positive top-line results for the Phase IIa CS1-003 trial, which evaluated the HDAC inhibitor CS1 in pulmonary arterial hypertension (PAH). The primary endpoint of safety... ► Artikel lesen | |
02.10. | Edison Investment Research increases valuation of Cereno Scientific to 3.9 BSEK or SEK 13.9 SEK/share after positive topline data | 1 | Cision News | ||
30.09. | Cereno's HDAC inhibitor reduces risks from pulmonary arterial hypertension in phase 2 trial | 2 | FierceBiotech | ||
30.09. | Save the date for Cereno Scientific's Capital Markets Day on October 17, 2024 | 1 | Cision News |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
ADMA BIOLOGICS | 22,620 | +14,71 % | ADMA Biologics-Aktie erreicht Allzeithoch von 21,25 US-Dollar | ||
QIAGEN | 40,750 | -1,18 % | Qiagen NV-Aktie heute gut behauptet: Aktienwert steigt (40,135 €) | Im Plus liegt gegenwärtig der Anteilsschein von Qiagen NV . Der jüngste Kurs betrug 40,14 Euro. Heute hat sich im Wertpapierhandel die Aktie von Qiagen NV zwischenzeitlich um 1,02 Prozent verteuert.... ► Artikel lesen | |
BEAM THERAPEUTICS | 27,060 | +3,68 % | Beam Therapeutics Inc. Q3 Loss Misses Estimates | WASHINGTON (dpa-AFX) - Beam Therapeutics Inc. (BEAM) reported Loss for third quarter that missed the Street estimates.The company's earnings came in at -$96.668 million, or -$1.17 per share.... ► Artikel lesen | |
ARVINAS | 27,140 | -2,20 % | Arvinas's SWOT analysis: biotech stock poised for pivotal trial results | ||
EVOTEC | 7,635 | -2,92 % | Evotec Aktie: Woche der Wahrheit | Für die Börse im Allgemeinen und die Evotec Aktie im Besonderen wird es eine Woche der Wahrheit: Die US-Wahlen am morgigen Dienstag werden richtungweisend und das Hamburger Biotech-Unternehmen legt... ► Artikel lesen | |
DYNE THERAPEUTICS | 28,480 | -2,70 % | Dyne Therapeutics Reports Positive Data From Phase 1/2 DELIVER Trial Of DYNE-251 In DMD | WASHINGTON (dpa-AFX) - Tuesday, Dyne Therapeutics, Inc. (DYN) revealed new clinical findings from its Phase 1/2 DELIVER trial of DYNE-251 for patients with Duchenne muscular dystrophy also known... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 7,100 | +2,45 % | Recursion Pharmaceuticals EPS of -$0.34 misses by $0.01, revenue of $26.1M misses by $3.73M | ||
AVIDITY BIOSCIENCES | 46,720 | -1,66 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2024 Financial Results and Recent Highlights | Enrollment in global Phase 3 HARBOR study for del-desiran in DM1 is on track
Avidity initiated biomarker cohort for del-brax FORTITUDE study for FSHD; pursuing a... ► Artikel lesen | |
NUVALENT | 95,42 | +1,41 % | Nuvalent-Finanzchefin Alexandra Balcom verkauft Aktien im Wert von 891.879 US-Dollar | ||
ARCUTIS BIOTHERAPEUTICS | 10,820 | +4,04 % | Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | WESTLAKE VILLAGE, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations... ► Artikel lesen | |
TARSUS PHARMACEUTICALS | 49,420 | +5,62 % | Tarsus Pharmaceuticals, Inc: Tarsus Appoints Elizabeth Yeu, M.D., as Chief Medical Officer | IRVINE, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to address unmet medical needs and apply proven science and new technology to revolutionize... ► Artikel lesen | |
DAY ONE BIOPHARMACEUTICALS | 16,390 | +4,00 % | Day One Biopharmaceuticals (NASDAQ:DAWN) Stock Rating Upgraded by TD Cowen | ||
NURIX THERAPEUTICS | 27,340 | +0,37 % | Nurix Therapeutics-Aktie erreicht 52-Wochen-Hoch von 27,61 US-Dollar | ||
SUMMIT THERAPEUTICS | 21,410 | +1,47 % | Summit Therapeutics Aktie: Verunsicherung steigt! | Summit Therapeutics, ein biopharmazeutisches Unternehmen, verzeichnet einen bemerkenswerten Aufschwung an der Börse. Die Aktie schloss am 9. November 2024 bei 21,41 USD, was einem Anstieg von 1,47%... ► Artikel lesen | |
VERA THERAPEUTICS | 48,090 | -1,94 % | Vera Therapeutics, Inc. - 10-Q, Quarterly Report |